Epigenetics is one of the most promising and expanding fields in the current biomedical
research landscape. Since the inception of epigenetics in the 1940s, the discoveries …

Histone deacetylases (HDACs) play an important role in regulating target gene expression.
They have been highlighted as a novel category of anticancer targets, and their inhibition …

Epigenetic alterations are strongly associated with the development of cancer. We
conducted a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat …

Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic
and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The …

Previous findings have suggested that class IIa histone deacetylases (HDACs)(HDAC4,-5,-
7, and-9) are inactive on acetylated substrates, thus differing from class I and IIb enzymes …

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …

Introduction Of the more than one million global cases of breast cancer diagnosed each
year, approximately fifteen percent are characterized as triple-negative, lacking the …

Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and
nonhistone proteins, controlling the transcription and regulation of genes involved in cell …

Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the
treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been …

Many cancers display increased expression of histone deacetylases (HDACs) and therefore
transcriptionally inactive chromatin, resulting in the downregulation of genes including …